Synthetase-transformylase enzyme required for the synthesis of fmet-tRNAF was isolated by the procedure of DUBNOFF and MAITRA8).
[3]finet-tRNAF was prepared as described by CASKEY et al. 9) and had a specific activity of approximately 900 cpm / pmole. Initiation factors were isolated from the first ribosomal salt wash fluid8). R17
phage RNA was purchased from Boehringer Mannheim. Following initial assay in specific cell-free test systems for protein and RNA synthesis the stock solution was stored at 4°C in the dark and reassayed at weekly intervals.
It was found that rubradirin is quite stable for a week under these conditions (Fig. 3) . Thereafter the inhibitory potency against peptide synthesis decreased significantly while the inhibitory potency for RNAP increased accordingly. Hence it was apparent that an unknown reaction caused the slow, gradual conversion from one compound into another.
The eventual determination of the chemical structure of rubradirin and the availability of key rubradirin fragments allowed us to rationalize these stability phenomena.
Effect of Rubradirin Fragments on Cell-free Macromolecular Biosynthetic Systems
Peptide synthesis was carried out in a NIRENBERG type system measuring poly(U)-directed incorpo-
Intact rubradirin strongly inhibited this system as expected (Table 1) .
On the other hand rubransarol A, the picolinic acid-coumarin and the picolinic acid-coumarinrubranitrose moieties showed only moderate inhibition of the reaction. This might be due to the pres- ence of small traces of contaminant intact rubradirin in these preparations. The aglycone of rubradirin caused significant inhibition of the test system although the extent of inhibition was clearly inferior to that of rubradirin itself.
Intact rubradirin did not impair RNA synthesis effected by E. coli RNAP ( Table 2 ). The aglycone of rubradirin on the other hand caused complete cessation of RNA synthesis. The remaining fragments showed marginal inhibition which might be attributable to trace impurities present in these preparations as reasoned above. The only exception is the picolinic acid-coumarin moiety which did inhibit the reaction to the extent of 61 % at 0.05 mm.
Lastly, we investigated the effect of the compounds under study on replicative DNA synthesis in toluenized E. coli cells. None of the fragments inhibited this system to a significant extent (Table 3) .
Novobiocin is a specific inhibitor of this system", `)In this context it is of interest to note that novobiocin contains a coumarin moiety as does rubradirin. This structure is essential in novobiocin for the exertion of inhibitory activity on DNA replication (REUSSER, unpublished results).
These experiments confirmed our earlier findings that intact rubradirin acts as a specific inhibitor of protein synthesis. In addition the results show that the aglycone of rubradirin is less active in inhibiting protein synthesis but strongly inhibits the function of the enzyme RNAP. We also established earlier that rubradirin specifically inhibits the formation of enzymatic peptide chain initiation complexes meaning that it prevents the formation of or dissociates preformed fmet-tRNAF-mRNA-ribosome complexes.
Rubradirin aglycone on the other hand inhibits non-enzymatic peptide chain initiation as well although only to a moderate extent (results not shown). (Table  1) .
Discussion
The antibiotic rubradirin contains an ansamycin-like moiety and is in this respect related to a family of antibiotics known as the ansamycins. Most members of this group (rifamycins, streptovaricins, tolypomycins) act as very potent inhibitors of bacterial RNAP13). Intact rubradirin, however, does not impair the function of RNAP but instead inhibits bacterial protein synthesis.
By contrast, the aglycone of rubradirin retains some inhibitory activity toward protein synthesis Reaction mixtures were as described in the legend to Table 6 . The DNA-RNAP complex was preformed by incubating the sample for 5 minutes at 37 C: antibiotics were then added, and incubation was continued for an additional 5 minutes. but proves to be an extremely potent inhibitor of the enzyme RNAP. The specific mode of action of rubradirin aglycone on RNAP differs significantly from the one exerted by streptolydigin or rifamycins.
These latter agents cause cessation of initiation or de novo RNA synthesis but do not prevent the binding of the polymerase to its initiation site on the DNA template14, 15). On the other hand rubradirin aglycone as well as congo red prevent the attachment of RNAP to its promoter sites on the DNA template and dissociate preformed DNA-RNAP complexes. The specific action of rubradirin aglycone on RNAP is thus more related to the one exerted by congo red and not to the ansamycins.
The highly methylated nitro-sugar present in rubradirin must play a pivotal role in the ability of rubradirin and its aglycone to either affect protein or RNA synthesis: In the glycosylated form the antibiotic inhibits protein synthesis only, as an aglycone it primarily inhibits RNA synthesis and inhibits protein synthesis to a lesser extent. Rubradirin B was also isolated from rubradirin fermentations in small quantities16). It lacks the hydroxyl group at position 4 of the dipicolinic acid which is glycosylated in rubradirin. Consequently it lacks rubranitrose. In addition, rubradirin B differs slightly from rubradirin itself in the stereochemistry at 07 of the ansachromophore which is trans in the case of rubradirin B (Fig. 1) . Surprisingly rubradirin B does not impair the function of RNAP at all but exclusively affects ribosomal functions and that to a much lesser extent than rubradirin. This observation suggests that the non-glycosylated hydroxyl group as present in rubradirin aglycone is probably essential for interaction with RNAP. The significance of the minor stereochemical difference between rubradirin and rubradirin B within the ansamycin chromophore is more difficult to assess. Rubradirin only prevents enzymatic peptide chain initiation and thereby affects the initiator site on the 30S ribosomal subunit.
In more general terms this region represents a nucleic acid binding site. The aglycone of rubradirin also impairs the ribosomal initiator site but shows less specificity toward this site as it inhibits enzymatic as well as non-enzymatic initiation.
In addition rubradirin aglycone possesses a very strong affinity for RNAP and more specifically for the template nucleic acid binding site of this enzyme. This latter conclusion is supported by the fact that the aglycone prevents the attachment of RNAP to its template.
Ribosomes and RNAP differ significantly from each other in terms of .structure and function.
However, the simplest interpretation of our results is that rubradirin aglycone interacts with the nucleic acid binding sites as present in RNAP and at the initiator tRNA binding site on the ribosome. Rubradirin on the other hand recognizes only the binding site as present on the initiating ribosome. This in turn suggests some common structural features for the respective nucleic acid binding pockets as present on either RNAP or the ribosome.
It is also interesting to note that neither of the two inhibitors under discussion inhibits DNA replication as assessed in a toluenized E. coli system. This infers that the template binding site of the replicase differs from the ones present in RNAP or the ribosomal initiator tRNA site.
In terms of antibacterial activity against whole bacterial cells rubradirin is an extremely potent growth inhibitor. The drug, is therefore, capable to penetrate the bacterial cell envelope. The aglycone of rubradirin, although extremely potent in cell-free systems, shows modest growth inhibitory activity vs. whole cells. This latter compound is thus an inefficient penetrator of the cellular envelope. 
